A Phase 1, Open-Label Study to Assess Pharmacokinetics After Single Doses of Pociredir in Participants With Sickle Cell Disease
Latest Information Update: 15 Apr 2026
At a glance
- Drugs Pociredir
- Indications Sickle cell anaemia
- Focus Pharmacokinetics
- Sponsors Fulcrum Therapeutics
Most Recent Events
- 30 Mar 2026 Planned End Date changed from 1 Apr 2026 to 1 Jun 2026.
- 30 Mar 2026 Planned primary completion date changed from 1 Mar 2026 to 31 May 2026.
- 02 Mar 2026 New trial record